Possible Treatment of Parkinson's Disease with Intrathecal Medication in the MPTP Model
dc.contributor.author | Hood, Terry W. | en_US |
dc.contributor.author | Domino, Edward F. | en_US |
dc.contributor.author | Greenberg, Harry S. | en_US |
dc.date.accessioned | 2010-06-01T20:49:02Z | |
dc.date.available | 2010-06-01T20:49:02Z | |
dc.date.issued | 1988-06 | en_US |
dc.identifier.citation | HOOD, TERRY W.; DOMINO, EDWARD F.; GREENBERG, HARRY S. (1988). "Possible Treatment of Parkinson's Disease with Intrathecal Medication in the MPTP Model." Annals of the New York Academy of Sciences 531(1 Neurological Applications of Implanted Drug Pumps ): 200-205. <http://hdl.handle.net/2027.42/73916> | en_US |
dc.identifier.issn | 0077-8923 | en_US |
dc.identifier.issn | 1749-6632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73916 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3260087&dopt=citation | en_US |
dc.format.extent | 323592 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 1988 The New York Academy of Sciences | en_US |
dc.title | Possible Treatment of Parkinson's Disease with Intrathecal Medication in the MPTP Model | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Science (General) | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Surgery (Section of Neurosurgery), Pharmacology and Neurology University of Michigan Medical School Ann Arbor, Michigan 48109 | en_US |
dc.identifier.pmid | 3260087 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73916/1/j.1749-6632.1988.tb31828.x.pdf | |
dc.identifier.doi | 10.1111/j.1749-6632.1988.tb31828.x | en_US |
dc.identifier.source | Annals of the New York Academy of Sciences | en_US |
dc.identifier.citedreference | Hornkiewicz, O. 1966. Metabolism of brain dopamine in human parkinsonism: Neurochemical and clinical aspects. In Biochemistry and Pharmacology of the Basal Ganglia. E. Costa, L. J. Cote & M. D. Yahr, Eds. 171 – 181. Raven Press. New York, NY. | en_US |
dc.identifier.citedreference | Marsden, C. D. & J. D. Parkes. 1976. “ On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1: 292 – 296. | en_US |
dc.identifier.citedreference | McDowell, F. H., J. E. Lee & R. D. Sweet. 1981. Extrapyramidal disease. In Clinical Neurology. A. B. Baker & L. H. Baker, Eds. Harper and Row. Philadelphia, PA. | en_US |
dc.identifier.citedreference | Rosin, A. J., D. Devereux, N. Eng & D. B. Calne. 1979. Parkinsonism with “on-off” phenomenonIntravenous treatment with levodopa after major abdominal surgery. Arch. Neurol. 36: 32 – 34. | en_US |
dc.identifier.citedreference | Obeso, J. A., M. R. Luquin & J. M. Martinez-Lage. 1986. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson's disease. Lancet 1: 467 – 470. | en_US |
dc.identifier.citedreference | Hargraves, R. W. & W. Freed. 1987. Chronic intrastriatal dopamine infusions reduce motor abnormalities in an animal model of Parkinson's disease. Presented at the Annual Meeting of the American Association of Neurological Surgeons. May 3–7. Dallas, TX. | en_US |
dc.identifier.citedreference | Langston, J. W., P. Ballard, J. W. Tetrud & I. Irwin. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979 – 980. | en_US |
dc.identifier.citedreference | Burns, R. S., C. C. Chiueh, S. P. Markey, M. H. Ebert, D. M. Jacobowitz & I. J. Kopin. 1983. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80: 4546 – 4550. | en_US |
dc.identifier.citedreference | Nutt, J. G., W. R. Woodward, J. P. Hammerstad, J. H. Carter & J. L. Anderson. 1984. The “on-off” phenomenon in Parkinson's diseaseRelation to levodopa absorption and transport. N. Engl. J. Med. 310: 483 – 488. | en_US |
dc.identifier.citedreference | Klawans, H. L., C. Goetz, P. H. Nausieda & W. J. Weiner. 1977. Levodopa-induced dopamine receptor hypersensitivity. Ann. Neurol. 2: 125 – 129. | en_US |
dc.identifier.citedreference | Nutt, J. G., W. R. Woodward & J. H. Carter. 1986. Clinical and biochemical studies with controlled release Sinemet. Neurology 36: 1206 – 1211. | en_US |
dc.identifier.citedreference | Juncos, J. L., G. Fabbrini, M. M. Mowradian, C. Serrati, A. M. Kask & T. N. Chase. 1987. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 50: 194 – 198. | en_US |
dc.identifier.citedreference | Quinn, N., C. D. Marsden & J. D. Parkes. 1982. Complicated response fluctuations in Parkinson's disease: Response to intravenous infusion of levodopa. Lancet 2: 412 – 415. | en_US |
dc.identifier.citedreference | Hood, T. W., E. F. Domino & H. S. Greenberg. 1987. Reversal of parkinsonism in the MPTP rhesus monkey model by intraventricular L-Dopa methyl ester. Presented at the Annual Meeting of the American Association of Neurological Surgeons. May 3–7. Dallas, TX. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.